ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SNSS Sunesis Pharmaceuticals Inc

5.32
0.00 (0.00%)
After Hours
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunesis Pharmaceuticals Inc NASDAQ:SNSS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.32 4.72 4.75 0 01:00:00

Initial Statement of Beneficial Ownership (3)

25/02/2021 11:04pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Roshwalb Gur
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/24/2021 

3. Issuer Name and Ticker or Trading Symbol

SUNESIS PHARMACEUTICALS INC [VIRX]
(Last)        (First)        (Middle)

C/O VIRACTA THERAPEUTICS, INC., 2533 S COAST HWY 101, SUITE 210
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

CARDIFF, CA 92007      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 2032865 I See Footnote (1)
Common Stock 5359372 I See Footnote (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) Shares are owned directly by aMoon - VRCT SPV Limited Partnership, for which the reporting person may be deemed to have voting and dispositive power. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.
(2) Shares are owned directly by aMoon 2 Fund Limited Partnership, for which the reporting person may be deemed to have voting and dispositive power. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.

Remarks:
Exhibit 24: Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Roshwalb Gur
C/O VIRACTA THERAPEUTICS, INC.
2533 S COAST HWY 101, SUITE 210
CARDIFF, CA 92007
XX


Signatures
/s/ Michael Mueller, as Attorney-in-Fact2/24/2021
**Signature of Reporting PersonDate

1 Year Sunesis Pharmaceuticals Chart

1 Year Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock